Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.48 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839044 | 0.86 | CYP17A1 (0.55) | TP53LMNAMAPTPOLBRAB9A | |
| SCHEMBL25343885 | 0.82 | PIP4K2A (0.54) | TP53LMNAPIP4K2AMAPT | |
| SCHEMBL839210 | 0.82 | GCK (0.47) | TP53LMNAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL25344174 | 0.80 | MAPT (0.58) | TP53LMNAPIP4K2AMAPT | |
| SCHEMBL11476904 | 0.78 | RAB9A (0.63) | TP53LMNAMAPTALOX12POLB | |
| SCHEMBL25341544 | 0.78 | CYP17A1 (0.45) | TP53LMNAMAPTPOLBRAB9A | |
| SCHEMBL30568414 | 0.77 | CYP17A1 (0.53) | TP53LMNAMAPTPOLBRAB9A | |
| SCHEMBL839701 | 0.77 | CYP17A1 (0.53) | TP53LMNAMAPTPOLBRAB9A | |
| SCHEMBL16363299 | 0.77 | MAPT (0.66) | TP53LMNAPIP4K2AMAPTRAB9A | |
| SCHEMBL838829 | 0.77 | P2RX7 (0.46) | TP53LMNAMAPTNPSR1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005047288-A1 | PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-05-26 | — | — | WO | claimed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2005047288-A1 | PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | TP53 4297/4885LMNA 3530/4885PIP4K2A 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.